Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$10.55
-4.5%
$11.69
$9.85
$17.15
$379.61M0.2778,886 shs42,178 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$11.28
-3.8%
$13.54
$6.43
$17.15
$341.09M0.97218,555 shs135,055 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$22.25
-6.0%
$24.91
$7.78
$34.10
$347.43M1.4156,632 shs178,203 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.97
+7.1%
$5.49
$3.90
$15.00
$117.45M0.69564,598 shs963,104 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
+6.25%-4.41%-9.43%-2.56%-28.62%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+4.36%-11.34%-18.99%-13.37%+64.98%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-2.55%-18.35%+6.14%+2.51%+153.43%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+11.90%+21.38%+69.58%+90.78%-26.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$10.55
-4.5%
$11.69
$9.85
$17.15
$379.61M0.2778,886 shs42,178 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$11.28
-3.8%
$13.54
$6.43
$17.15
$341.09M0.97218,555 shs135,055 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$22.25
-6.0%
$24.91
$7.78
$34.10
$347.43M1.4156,632 shs178,203 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.97
+7.1%
$5.49
$3.90
$15.00
$117.45M0.69564,598 shs963,104 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
+6.25%-4.41%-9.43%-2.56%-28.62%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+4.36%-11.34%-18.99%-13.37%+64.98%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-2.55%-18.35%+6.14%+2.51%+153.43%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+11.90%+21.38%+69.58%+90.78%-26.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.63
Moderate Buy$27.00155.92% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.75
Moderate Buy$20.2979.84% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.33
Hold$47.50113.48% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-49.85% Downside

Current Analyst Ratings Breakdown

Latest LFVN, BNTC, GLSI, and ENTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/15/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Reiterated RatingSell (D-)
5/12/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Initiated CoverageOutperform$25.00
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
4/20/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Reiterated RatingSell (D-)
4/20/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Reiterated RatingSell (D-)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/26/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Initiated CoverageBuy$20.00
3/9/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Reiterated RatingBuy
3/9/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Reiterated RatingBuy$32.00
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$3.71 per shareN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$65.32M5.02N/AN/A$3.03 per share3.72
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.55$1.32 per share7.57$2.75 per share3.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$37.92M-$1.14N/AN/AN/AN/A-34.82%-34.11%N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.43N/AN/AN/AN/A-1,042.84%-565.43%6/9/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4522.1615.34N/A2.94%23.89%12.47%N/A

Latest LFVN, BNTC, GLSI, and ENTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/9/2026Q4 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.67-$0.34-$0.67$0.00 millionN/A
6/1/2026Q4 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A-$0.58N/A-$0.58N/AN/A
5/14/2026Q3 2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.27-$0.24+$0.03-$0.24$4.55 millionN/A
5/11/2026Q2 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.202.01%N/A44.44%3 Years

Latest LFVN, BNTC, GLSI, and ENTA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/A
56.82
56.82
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
3.84
3.84
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
2.35
2.35
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04

Institutional Ownership

CompanyInstitutional Ownership
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
4.80%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
11.48%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2034.35 million32.71 millionNo Data
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16029.08 million25.74 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
314.68 million7.12 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable

Recent News About These Companies

Lifevantage (LFVN) Stock Forecast & Price Target
LFVN Share News Today
Lifevantage Stock Price History
Lifevantage Q3 Earnings Call Highlights
LifeVantage (LFVN) Q3 2026 Earnings Transcript
LifeVantage Declares Quarterly Dividend
LifeVantage Q3 2026 earnings preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$10.55 -0.50 (-4.52%)
Closing price 04:00 PM Eastern
Extended Trading
$10.58 +0.04 (+0.33%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$11.28 -0.45 (-3.84%)
Closing price 04:00 PM Eastern
Extended Trading
$11.28 0.00 (-0.04%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$22.25 -1.42 (-6.00%)
Closing price 04:00 PM Eastern
Extended Trading
$22.38 +0.13 (+0.56%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$9.97 +0.66 (+7.09%)
Closing price 04:00 PM Eastern
Extended Trading
$9.90 -0.07 (-0.71%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.